Filtered By:
Drug: Rituxan
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 5018 results found since Jan 2013.
Impact of T-cell Engagers on COVID-19-related Mortality in B-cell Lymphoma Patients Receiving B-cell Depleting Therapy
CONCLUSION: B-cell lymphoma patients treated with TCE had significantly worse outcomes from COVID-19 than those treated with RTX. TCE therapy should be used with caution in B-cell lymphoma patients during the COVID-19 epidemic.PMID:37448122 | DOI:10.4143/crt.2023.738
Source: Cell Research - July 14, 2023 Category: Cytology Authors: Chan Mi Lee Pyoeng Gyun Choe Chang Kyung Kang Hyeon Jae Jo Nam Joong Kim Sung-Soo Yoon Tae Min Kim Wan Beom Park Myoung-Don Oh Source Type: research
Targeted therapy in glomerular diseases
J Formos Med Assoc. 2023 Jul 11:S0929-6646(23)00248-6. doi: 10.1016/j.jfma.2023.06.020. Online ahead of print.ABSTRACTTargeted therapy has emerged as a more precise approach to treat glomerular diseases, focusing on specific molecular or cellular processes that contribute to disease development or progression. This approach complements or replaces traditional immunosuppressive therapy, optimizes supportive care, and provides a more personalized treatment strategy. In this review, we summarize the evolving understanding of pathogenic mechanisms in immune-mediated glomerular diseases and the developing targeted therapies bas...
Source: J Formos Med Assoc - July 13, 2023 Category: General Medicine Authors: Yi-Chan Lin Tyng-Shiuan Gau Zheng-Hong Jiang Kuan-Yu Chen Yi-Ting Tsai Kuan-Yu Lin Hung-Ning Tung Fan-Chi Chang Source Type: research
Enzyme - Switch sensors for therapeutic drug monitoring of immunotherapies
In conclusion, the BLA-BLIP sensors provide a rapid biosensor for TDM of trastuzumab and ipilimumab with the potential to improve therapy. The sensitivity of this platform alongside its rapid action would be suitable for bedside monitoring in a point-of-care (PoC) setting.PMID:37419072 | DOI:10.1016/j.bios.2023.115488
Source: Biosensors and Bioelectronics - July 7, 2023 Category: Biotechnology Authors: Emma Campbell Hope Adamson Declan Kohl Christian Tiede Christoph W älti Darren C Tomlinson Lars J C Jeuken Source Type: research
Risk factors for relapse in non-infectious cryoglobulinemic vasculitis, including type I cryoglobulinemia: a systematic review
ConclusionOur findings underscore the significance of attaining both clinical and immunological responses and identifying risk factors for relapse in NICV. Appropriate risk stratification for NICV patients is essential for the successful implementation of effective treatment strategies.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023408140.
Source: Frontiers in Immunology - July 7, 2023 Category: Allergy & Immunology Source Type: research
Successful Blinatumomab treatment in an allogeneic hematopoietic stem cell transplant recipient with EBV-related post-transplant lymphoproliferative disorder: A case report and literature review
Transpl Immunol. 2023 Jul 4:101895. doi: 10.1016/j.trim.2023.101895. Online ahead of print.ABSTRACTPost-transplant lymphoproliferative disorder (PTLD) is a condition in which patients experience the unrestrained proliferation of B cells as a consequence of impaired immune surveillance, almost always as a consequence of Epstein-Barr virus (EBV) infection. It remains one of the most serious potential complications that patients can experience after undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). While treatment with rituximab can significantly improve the prognosis of individuals with EBV-PTLD, tho...
Source: Transplant Immunology - July 6, 2023 Category: Transplant Surgery Authors: Shulian Chen Licai An Jie Han Xiaohui Zheng Xiaoyu Zhang Gang Li Ying Zhang Wenbin Cao Mengnan Lv Donglin Yang Erlie Jiang Aiming Pang Sizhou Feng Source Type: research
Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis
CONCLUSION: We found high heterogeneity among studies comparing rituximab, abatacept, and tocilizumab. On multivariate metaregressions, if the conditions of the RCTs were similar, we estimate that abatacept could increase the chance of reaching an ACR70 response by 2.2-fold compared to tocilizumab.PMID:37415193 | DOI:10.1186/s42358-023-00298-z
Source: Adv Data - July 6, 2023 Category: Epidemiology Authors: Alisson Pugliesi Amanda Borges de Oliveira Ana Beatrice Oliveira Ricardo Xavier Licia Maria Henrique da Mota Manoel Barros Bertolo Miguel Angel Gonzalez-Gay Gustavo Citera Luiz Sergio Fernandes de Carvalho Source Type: research
Successful Blinatumomab treatment in an allogeneic hematopoietic stem cell transplant recipient with EBV-related post-transplant lymphoproliferative disorder: A case report and literature review
Transpl Immunol. 2023 Jul 4:101895. doi: 10.1016/j.trim.2023.101895. Online ahead of print.ABSTRACTPost-transplant lymphoproliferative disorder (PTLD) is a condition in which patients experience the unrestrained proliferation of B cells as a consequence of impaired immune surveillance, almost always as a consequence of Epstein-Barr virus (EBV) infection. It remains one of the most serious potential complications that patients can experience after undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). While treatment with rituximab can significantly improve the prognosis of individuals with EBV-PTLD, tho...
Source: Transplant Immunology - July 6, 2023 Category: Transplant Surgery Authors: Shulian Chen Licai An Jie Han Xiaohui Zheng Xiaoyu Zhang Gang Li Ying Zhang Wenbin Cao Mengnan Lv Donglin Yang Erlie Jiang Aiming Pang Sizhou Feng Source Type: research
Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis
CONCLUSION: We found high heterogeneity among studies comparing rituximab, abatacept, and tocilizumab. On multivariate metaregressions, if the conditions of the RCTs were similar, we estimate that abatacept could increase the chance of reaching an ACR70 response by 2.2-fold compared to tocilizumab.PMID:37415193 | DOI:10.1186/s42358-023-00298-z
Source: Adv Data - July 6, 2023 Category: Epidemiology Authors: Alisson Pugliesi Amanda Borges de Oliveira Ana Beatrice Oliveira Ricardo Xavier Licia Maria Henrique da Mota Manoel Barros Bertolo Miguel Angel Gonzalez-Gay Gustavo Citera Luiz Sergio Fernandes de Carvalho Source Type: research
Treatment of new-onset primary central nervous system lymphoma in elderly patients using RMPV chemotherapy: a single-institution experience
Int J Hematol. 2023 Jul 1. doi: 10.1007/s12185-023-03632-9. Online ahead of print.ABSTRACTThe prognosis of primary central nervous system lymphoma (PCNSL) in the elderly remains poor. We aimed to evaluate the outcome of rituximab, methotrexate, procarbazine, and vincristine (RMPV) chemotherapy in elderly patients with new-onset PCNSL. Twenty-eight patients aged ≥ 70 years treated for PCNSL between 2010 and 2020 were examined retrospectively. Nineteen patients received RMPV and nine did not qualify. Patients received five to seven cycles of RMPV plus response-adapted whole-brain radiotherapy (WBRT) and cytarabine. Ten of ...
Source: International Journal of Hematology - July 1, 2023 Category: Hematology Authors: Michiharu Yoshida Takeharu Kato Takeshi Hiu Yoshitaka Imaizumi Simpei Morimoto Daisuke Niino Susumu Yamaguchi Shiro Baba Kenta Ujifuku Koichi Yoshida Ayaka Matsuo Yoichi Morofuji Tsuyoshi Izumo Shinji Okano Yasushi Miyazaki Takayuki Matsuo Source Type: research
Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal
Ther Adv Med Oncol. 2023 Jun 22;15:17588359231183565. doi: 10.1177/17588359231183565. eCollection 2023.ABSTRACTExtranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) is among the more common types of lymphoma accounting for up to 8% of newly diagnosed lymphoma cases. As opposed to other B-cell lymphomas, however, no predominant genetic hallmark has been defined in MALT lymphoma, but different localizations appear to be affected by different, sometimes distinct changes. Nonetheless, a high proportion of these genetic changes reported in MALT lymphomas dysregulate the pathways leadi...
Source: Adv Data - June 30, 2023 Category: Epidemiology Authors: Markus Raderer Barbara Kiesewetter Ming-Qing Du Source Type: research
